Home » Biologics Discovery » Pharmacology & Discovery Reagent Service » In Vitro Pharmacology » Immune Checkpoint Primary Cell Assay

Immune Checkpoint Primary Cell Assay

Characterizing biological therapeutics by optimized in vitro functional assays has been utilized to intermediately predict clinical outcomes and immunogenicity risks in a readily performed way. Peripheral blood mononuclear cells, isolated from human blood, consist of diverse immune cells, and are a powerful in vitro model in immunological research, biomarker identification and drug discovery. ProBio offers highly customized approaches to monitor the induction of immune responses with considerable performance characteristics of your biological candidates.

Mechanism of Action

MoA of anti-immune checkpoint antibodies (Cancer Immunotherapy).

	Service Details
Assay Types	Immune cell stimulation assay, MLR
Stimulator	CD3/CD28 beads (or anti-CD3 and anti-CD28 antibodies), PMA/ionomycin, LPS, TNF-α, IL-1β, IL-2, Antigens, Mature dendritic cells (mDC)
Responder	PBMC, CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, Treg cells, DC, Macrophages
Assessment	Cell proliferation (CellTiter-Glo, CFSE), Cytokine release (ELISA/Luminex), Immunophenotyping

Service Features and Advantages

A professional team with extensive project experiences from hundreds of projects;
Free negative and positive antibody controls;
Valid source of primary cells, approved BSL-2 laboratories, IND-filing complied;
Multiple IQ, OQ and PQ-certified plate readers with audit trail functions;
Provide customized services according to client’s needs with guaranteed delivery.

Please download the project evaluation form, fill it and send it to us for an evaluation

Case Study

Case 1. Characterizations of OX40 antibody by T cell stimulation assay

OX40 receptors are co-stimulatory immune checkpoints on activated immune cells. Triggering OX40-mediated signaling pathways on T cells leads to enhanced cytokine production and T cell expansion.

Figure 1. Anti-OX40 antibody enhanced IFN-y production (left) and cell proliferation of CD4+ T cells (right) in a dose-dependent manner.

Case 2. Characterizations of PD-1 antibody by MLR assay

PD1/PDL1 pathway is a typical mechanism of tumor immune escape. PD1/PDL1 inhibitors boost anti-tumor immunity through recovering adaptive immune responses.

Figure 2. Anti-PD1 antibody enhanced IL-2 (left) and IFN-y (right) productions in MLR assay.